Prosecution Insights
Last updated: November 11, 2026
Application No. 16/620,187

Cell Composition, Method of Production and its Use in Corneal Diseases

Final Rejection §112
Filed
Dec 06, 2019
Priority
Jun 09, 2017 — IN 201741020290 +1 more
Examiner
WANG, CHANG YU
Art Unit
1675
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hyderabad Eye Institute
OA Round
6 (Final)
33%
Grant Probability
At Risk
7-8
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allowance Rate
293 granted / 879 resolved
-26.7% vs TC avg
Strong +54% interview lift
Without
With
+53.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
75 currently pending
Career history
964
Total Applications
across all art units

Statute-Specific Performance

§101
4.7%
-35.3% vs TC avg
§103
27.1%
-12.9% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
35.7%
-4.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 879 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION RESPONSE TO AMENDMENT Status of Application/Amendments/claims 2. Applicant’s amendment filed June 23, 2026 is acknowledged. Claims 3-11, 16-18, 23, 29-30, 32 and 34-35 are canceled. Claims 12-13, 24 and 27 are amended. Claims 1-2, 12-15, 19-22, 24-28, 31, 33 and 36-37 are pending in this application. Claims 1-2, 14-15, 19-22, 25-26, 28, 31, 33 and 36-37 are withdrawn without traverse (filed 02/22/2022) from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on February 2, 2022. 3. Claims 12-13, 24 and 27 are under examination in this office action. 4. Applicant’s arguments filed on June 23, 2026 have been fully considered but they are not deemed to be persuasive for the reasons set forth below. Priority 5. Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 365(c) as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, IN201741020290 filed 06/09/2017, fails to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. 112 for one or more claims of this application. The instant application claims a method of preparing a cell composition consisting of a first layer and a second layer, comprising a) preparing a mixture comprising thrombin and a plurality of limbal derived stromal cells (LSCs) expressing markers CK3+12, ABCG2, PAX6 and VIMENTIN; b) preparing a mixture comprising a plurality of limbal derived epithelial cells (LECs) and fibrinogen; c) depositing the mixture of step a) as the first layer and d) depositing the mixture of step b) on the first layer to provide the second layer of the composition, wherein the LCSs and LECs are present at a ratio ranging from 1:5 to 5:1; and thrombin and fibrinogen are present at a ratio ranging from 1:5 to 5:1, which is not presented in the IN201741020290 filed 06/09/2017. IN201741020290 filed 06/09/2017 only disclosed “the epithelial cell pellet was ticturate using 0.05ml of thrombin solution….the mesenchymal cell pellet was mixed in 0.05ml of the fibrinogen component of commercially available fibrin tissue sealant….The fibrinogen component containing the mesenchymal cells was placed first one-drop at a time …was covered by placing epithelial cell in the appropriate concentration in the thrombin component…”(p. 6 of IN201741020290 filed 06/09/2017). The instant specification (PCT/IB2018/054183 filed 06/09/2018) only disclosed “a multilayer cell composition comprising (a) a firs layer comprising a plurality of limbal derived stromal cells and thrombin; and (b) a second layer comprising a plurality of limbal derived epithelial cells and fibrinogen” and a method for preparing the multilayer cell composition by depositing a first layer comprising a plurality of limbal derived stromal cells and thrombin. Further, a second layer comprising a plurality of limbal derived epithelial cells and fibrinogen is deposited over the first layer” (see p. 3 of the specification of PCT/IB2018/054183 or WO2018/225042) and “the preparation and delivery of the multi-layer composition to a subject patient was done simultaneously”, “…100ul of stromal stem cells were taken. 40-50ul of thrombin was added to the stromal stem cells…The composition forms the first layer of the multi-layered composition” and “…200ul of epithelial stem cells was taken. 40-50 ul of fibrinogen was added….This composition forms the second layer of the multi-layered composition…A uniform layer of stromal cell composition (first layer)…the cornea…a uniform layer of the epithelial cell composition (second layer) was applied on the affected part of the cornea” (p. 14-15 of PCT/IB2018/054183 or WO2018/225042 filed 06/09/2018). The instantly claimed method was only recited in instant claims. Claim Rejections/Objections Withdrawn 6. The rejection of claims 12, 32 and 34-35 under 35 U.S.C. 103 as being unpatentable over Xie’2012 (Invest Ophthalmol. Vis. Sci. 2012; 53:279-286) in view of Xie’2011 (Stem Cell, 2011; 29:1874-1885), Zhang et al. (US2017/0233698) and Funderburgh et al. (The Ocular Surface, 2016; 14:113-120) is withdrawn in response to Applicant’s amendment to the claims and cancelation of claims 32 and 34-35. The rejection of claims 24, 27 and 29 under 35 U.S.C. 103 as being unpatentable over Xie’2012 in view of Xie’2011, Zhang and Funderburgh as applied to claims 12, 32 and 34-35 above, and further in view of Deng (US2015/0175965) and Basu (2014) is withdrawn in response to Applicant’s amendment to the claims and cancelation of claim 29. The rejection of claims 12-13, and 30 under 35 U.S.C. 103 as being unpatentable over Xie’2012 in view of Xie’2011, Zhang, Funderburgh, Deng and Basu, and further in view of Claeyssens (US2015/0118197), Frank (US11129854) and Omoto et al. (2009) is withdrawn in response to Applicant’s amendment to the claims and cancelation of claim 30. New Grounds of Rejection Necessitated by the Amendment The following rejections are new grounds of rejections necessitated by the amendment filed on June 23, 2026. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 12-13, 24 and 27 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. Claims 12-13, 24 and 27 as amended are drawn to a method of preparing a cell composition consisting of a first layer and a second layer, the method comprising: a) preparing a mixture comprising thrombin and a plurality of limbal derived stromal cells (LSCs) expressing markers CK3+12, ABCG2, PAX6 and VIMENTIN; b) preparing a mixture comprising a plurality of limbal derived epithelial cells (LECs) and fibrinogen; c) depositing the mixture of step a) as the first layer of the cell composition; and d) depositing the mixture of step b) on the first layer to provide the second layer of the cell composition; wherein the LSCs and the LECs are present in the cell composition at a ratio ranging from 1:5 to 5:1; and wherein thrombin and fibrinogen are present in the cell composition at a ratio ranging from 1:5 to 5:1. The instant claims now recite new limitations “a cell composition consisting of a first layer and a second layer….. a) a mixture comprising thrombin and a plurality of limbal derived stromal cells (LSCs) expressing markers CK3+12, ABCG2, PAX6 and VIMENTIN;…….b) a mixture comprising a plurality of limbal derived epithelial cells (LECs) and fibrinogen; c)….at a ratio ranging from 1:5 to 5:1”, which were not clearly disclosed in the specification and claims as filed, and now change the scope of the instant disclosure as filed. Such limitations recited in the present claims, which did not appear in the specification or original claims, as filed, introduce new concepts and violate the description requirement of the first paragraph of 35 U.S.C. 112. The specification fails to disclose the new limitations. The specification only disclosed “a multilayer cell composition comprising (a) a firs layer comprising a plurality of limbal derived stromal cells and thrombin; and (b) a second layer comprising a plurality of limbal derived epithelial cells and fibrinogen” and a method for preparing the multilayer cell composition by depositing a first layer comprising a plurality of limbal derived stromal cells and thrombin. Further, a second layer comprising a plurality of limbal derived epithelial cells and fibrinogen is deposited over the first layer” (see p. 3 of the specification of PCT/IB2018/054183 or WO2018/225042) and “the preparation and delivery of the multi-layer composition to a subject patient was done simultaneously”; “…100ul of stromal stem cells (4000-5000 cells/ul) were taken. 40-50ul of thrombin (TISSEELTM kit) was added to the stromal stem cells…The composition forms the first layer of the multi-layered composition”; and “…200ul of epithelial stem cells was taken. 40-50 ul of fibrinogen (TISSEELTM kit) was added….This composition forms the second layer of the multi-layered composition…A uniform layer of stromal cell composition (first layer)…the cornea…a uniform layer of the epithelial cell composition (second layer) was applied on the affected part of the cornea” (p. 14-15, Examples 4-5 of the instant specification). Accordingly, in the absence of sufficient recitations for the new limitations “… a cell composition consisting of a first layer and a second layer….. a) a mixture comprising thrombin and a plurality of limbal derived stromal cells (LSCs) expressing markers CK3+12, ABCG2, PAX6 and VIMENTIN;…….b) a mixture comprising a plurality of limbal derived epithelial cells (LECs) and fibrinogen; c)….at a ratio ranging from 1:5 to 5:1”, the specification does not provide adequate written description to support the new limitations recited in claim 1. Support is not found for the new limitations as disclosed in the original specification and thus the recitations constitute new matter absent evidence for their support. Applicant is required to cancel the new matter in the reply to this office action. Alternatively, Applicant is invited to clearly point out the written support for the instant limitations. Conclusion 8. NO CLAIM IS ALLOWED. 9. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Basu et al. (Sci. Transl. Med. 2014; 6:266ra172, as in IDS) teaches a method of preparing and engrafting human limbal biopsy-derived stromal stem cells (LBSCs) in a subject in vivo, comprising a) preparing a mixture comprising LBSCs (5x104 cells) in a solution of human fibrinogen (20mg/ml); b) after wounding, adding 0.5ul of thrombin (100U/ml) to the wound bed; c) adding 1ul of fibrinogen with LBSCs; d) after 1-2 min, the fibrinogen had gelled; e) a second round of thrombin and fibrinogen was added as repeating steps b) and c) and the corneal epithelium closed the wound in 24-36 hours (see p. 8, 2nd col., Fibrin gel and LBSC application; p. 2, 2nd col. Human LBSCs engraft in murine cornea in vivo to p. 3; p. 1, 2nd col to p. 2, 2nd col. to p. 3; p.5-6, figures 4-6). Zhang et al. (US2017/0233698) teach a method of preparing a cell composition comprising a plurality of limbal stem cells and a plurality of limbal corneal epithelial cells for treating different ocular damage or diseases or ocular surface impairment including corneal ulcers including stromal ulceration, peripheral ulcerative or inflammatory keratitis, the method comprising i) obtaining cultured limbal stem cells (LSCs) which comprise limbal stromal stem cells (LSSCs) and limbal epithelial stem cells (LESCs), dissociating to single cells; ii) placing the isolated LCSs in and/or on a matrix or extracellular matrix to form 3D cell culture and culturing LSCs on a tissue base in an enriched medium or in a LSC differentiation medium to differentiate LSCs to corneal epithelial cells (CECs), wherein the matrix or extracellular matrix includes fibrinogen and thrombin and wherein the tissue base includes a fibrin gel comprising corneal stromal fibroblasts, derivatives of mesenchymal tissue, and epithelial cells, such as corneal epithelial cells (see paragraphs [0105]; [0140]; [0144]; [0148]; [0150]-[0153]; [0127]; [0250]-[0253]; [0255]-[0256]; [0162]-[0165]; [0181]-[0187]; [0225]; [0209]-[0237]). Zhang teaches that the LSCs express PAX6, ABCG2, CK3+12 (K3 and K12) (see paragraphs [0105]; [0140]; [0144]; [0148];[0162]). Zhang teaches cell transplantation by using 5x105 rabbit GFP-labeled LSCs, PAX6+ SESCs or shPAX6 LSCs cells mixed with fibrin (25 mg/ml) and thrombin (25 U/ml) (i.e. fibrin: thrombin=1:1) and seeded onto the exposed stromal bed of a recipient cornea and limbal area (see paragraph [0311]). Funderburgh et al. (The Ocular Surface, 2016; 14:113-120) teaches limbal stromal stem cells expressing ABCG2, PAX6 (p. 114, figure 1; p. 115, 1st col. section C. Tissue localization of stromal stem cells). Funderburgh teaches that the proximity of corneal stromal stem cells (CSSCs) and limbal epithelial stem cells (LESCs) in vivo suggests the possibility that each of these populations provides symbiotic support for maintenance of the stem cell phenotype of the other (see p. 117, 1st col., lines 13-16). Funderburgh teaches that in vitro, limbal fibroblasts supported expansion of LESCs better than 3T3 cells or scleral fibroblasts, and this ability was enhanced by expansion of the CSSCs in culture conditions that maintain the stem-like phenotype of the CSSCs (p. 118, 1st co., IV. Summary and Conclusions). Xie’2012 (Invest Ophthalmol. Vis. Sci. 2012; 53:279-286) teaches a method of preparing a cell composition comprising mixing a plurality of human limbal stromal mesenchymal cells (i.e. human limbal derived stromal cells (LSCs)) and a plurality of human limbal epithelial stem/progenitor cells (LECs) at a ratio of 1:4 and culturing the mixed cells at a density of 5x105 cells/cm2 in 3D Matrigel containing MESCM (modified embryonic stem cell medium) for 10 days (see p. 280, 1st col., section: coated, 2D and 3D Matrigel Culture and Treatment; p.280, 1st col., 1st paragraph-2nd paragraph; p. 279, 2st col., Results to p. 285, 2nd col.), wherein the human LSCs express CK12, PAX6 and VIMENTIN (Vim+), which are the limbal stromal mesenchymal stem cells or limbal derived stromal cells (LSCs) as instantly claimed (p. 279, abstract; p.281, 1st col-2nd col.; figure 2). Deng (US2015/0175965) teaches a method of preparing a multilayer cell composition comprising: disposing human limbal stem cells (LSCs) including human limbal epithelial stem cells (LECs) in the first cell culture compartment, disposing human feeder cells including human limbal stromal stem cells (LSCs) in the second cell culture compartment, wherein the human feeder cells include limbal stromal cells (LSCs) including limbal stromal mesenchymal stem cells(LSMSCs) or human limbal fibroblasts (HLFs), wherein the human feeder cells are below the human limbal stem cells (LSCs), which are related to instant claims (see [0016]; [0011]-[0016]; [0032]-[0039]; [0041]; [0077]-[0089]; Examples 1-2). Claeyssens (US2015/0118197) teaches an electrospun scaffold comprising limbal stem cells and mesenchymal stem cells for treatment of ocular injury (see paragraphs [0030]-[0033], [0107]-[0108]; claims 29-38), and also teaches that rabbit limbal fibroblasts were seeded on the scaffolds at a concentration of 1x105cells/ring, 8x104 cells/well and 25x104 or 5x104 cells and epithelial cells were seeded at a concentration of 5x104 cells/ring or 5x104 cells (i.e. 2:1 or 1:1 or 5:1 or 1.6:1) (see paragraphs [0168]; [0139]-[0142]) and microfabricated scaffolds treated with 10ul fibrin +10ul thrombin (see paragraph [0170]). Frank (US11129854) teaches 1-107 cells, 10-107, 10-106, 10-105,10-104, 10-102, 10, 102, 103, 104, 105, 106, 107 or more of ABCB5(+) limbal stem cells (LSCs) including LESCs and LSSCs and ABCB5(+) retinal epithelial stem cells are prepared and administered in a form of preparation or graft for treatment of limbal stem cell deficiency (LSCD) or ocular diseases (col. 9, lines 1-30; 11, lines 1-39). Omoto et al. (Invest. Ophthalmol. Vis. Sci. 2009; 50:2019-2115) teaches the use of a density of 105 cells/well, 2.5x104cells/cm2 and 1000 human limbal epithelial cells (see p. 5, 1st col), and also teaches engineering of human or rabbit epithelial cell sheets by coating cell culture inserts with 300ul fibrin, seeding 5x105 feeder cells at the bottom of well and adding 2x104 cells/cm2 human limbal epithelial cells (i.e. 25:1) for transplantation (see p. 5, 2nd col. 2nd paragraph). 10. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHANG-YU WANG whose telephone number is (571)272-4521. The examiner can normally be reached Monday-Thursday, 7:00am-5:00pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at 571-272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Chang-Yu Wang September 22, 2026 /CHANG-YU WANG/Primary Examiner, Art Unit 1675
Read full office action

Prosecution Timeline

Show 10 earlier events
Nov 18, 2024
Final Rejection mailed — §112
Feb 14, 2025
Request for Continued Examination
Feb 18, 2025
Response after Non-Final Action
Dec 23, 2025
Non-Final Rejection mailed — §112
Apr 08, 2026
Interview Requested
Jun 23, 2026
Response Filed
Sep 24, 2026
Final Rejection mailed — §112
Sep 24, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774323
APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF
2y 7m to grant Granted Oct 27, 2026
Patent 12662528
NOVEL ANTI-NOGO-A ANTIBODIES
4y 2m to grant Granted Jun 23, 2026
Patent 12662678
HUMAN ALZHEIMER'S DISEASE AND TRAUMATIC BRAIN INJURY ASSOCIATED TAU VARIANTS AS BIOMARKERS AND METHODS OF USE THEREOF
3y 6m to grant Granted Jun 23, 2026
Patent 12655201
ISOLATED ANTIGEN BINDING PROTEIN AND USE THEREOF
3y 6m to grant Granted Jun 16, 2026
Patent 12653872
MIMOTOPES OF ALPHA-SYNUCLEIN AND VACCINES THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHY
3y 6m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
33%
Grant Probability
87%
With Interview (+53.8%)
3y 10m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 879 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month